Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | VP, Finance & CAO | August 07, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date August 07, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,080 |
Reported balance
After 2026-08-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 730 · Balance 5,080 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 8/7/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2: These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 8/7/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 13, 2026 00:04 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 730 | $0.00 | $0.00 |
DisclosureSEC source: 0000318154-26-000135 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,080 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 8/7/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:17 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 41 | $331.11 | $13,575.51 |
DisclosureSEC source: 0000318154-26-000093 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,344 F1 · balance_after: These shares include 39 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 06, 2026 Filed May 8, 2026 01:06 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 50 | $329.59 | $16,479.50 |
DisclosureSEC source: 0000318154-26-000080 · form4.xml · nonDerivative · entry 2 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,385 F2 · balance_after: These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2026 Filed May 8, 2026 01:06 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 2,969 | $329.59 Strike: $329.59 | $978,552.71 |
DisclosureSEC source: 0000318154-26-000080 · form4.xml · derivative · entry 3 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,969 Underlying: Common Stock · 2,969 shares Expires 2036-05-05 F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. Read SEC document |
| May 05, 2026 Filed May 8, 2026 01:06 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 455 | $0.00 | $0.00 |
DisclosureSEC source: 0000318154-26-000080 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,435 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| May 02, 2026 Filed May 6, 2026 00:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 38 | $329.82 | $12,533.16 |
DisclosureSEC source: 0000318154-26-000060 · form4.xml · nonDerivative · entry 2 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,980 F1 · balance_after: These shares include 49 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2026 Filed May 6, 2026 00:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 30 | $329.82 | $9,894.60 |
DisclosureSEC source: 0000318154-26-000060 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,018 Read SEC document |
| March 16, 2026 Filed Mar 19, 2026 00:26 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 327 | $366.21 | $119,750.67 |
DisclosureSEC source: 0000318154-26-000024 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,048 F1 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 01:16 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 938 | $0.00 | $0.00 |
DisclosureSEC source: 0000318154-26-000013 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,361 F1 · balance_after: These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:43 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $375.79 | $375,790.00 |
DisclosureSEC source: 0000318154-26-000011 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,423 F1 · balance_after: These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 05, 2025 Filed Nov 8, 2025 00:54 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 202 | $296.70 | $59,933.40 |
DisclosureSEC source: 0000318154-25-000075 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,414 F1 · balance_after: These shares include 51 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 3,585 | $270.44 Strike: $270.44 | $969,527.40 |
DisclosureSEC source: 0001127602-25-013779 · form4.xml · derivative · entry 2 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,585 Underlying: Common Stock · 3,585 shares Expires 2035-05-06 F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/6/2026. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013779 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,588 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2025 Filed May 7, 2025 00:07 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $279.69 | $279,690.00 |
DisclosureSEC source: 0001127602-25-013526 · form4.xml · nonDerivative · entry 3 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,034 F1 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2025 Filed May 7, 2025 00:07 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 37 | $283.78 | $10,499.86 |
DisclosureSEC source: 0001127602-25-013526 · form4.xml · nonDerivative · entry 2 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,034 Read SEC document |
| May 02, 2025 Filed May 7, 2025 00:07 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 28 | $283.78 | $7,945.84 |
DisclosureSEC source: 0001127602-25-013526 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,071 Read SEC document |
| April 30, 2025 Filed May 3, 2025 01:24 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 18 | $288.56 | $5,194.08 |
DisclosureSEC source: 0001127602-25-013279 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,099 F1 · balance_after: These shares include 105 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:14 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 174 | $313.71 | $54,585.54 |
DisclosureSEC source: 0001127602-25-010052 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,117 F1 · balance_after: These shares include 111 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:56 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 497 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-008421 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277 F1 · balance_after: These shares include 100 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 00:45 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 189 | $316.91 | $59,895.99 |
DisclosureSEC source: 0001127602-24-026627 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,770 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Plan): 43 RSUs which will vest on 4/30/2025; 509 RSUs which will vest on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027; and 333 RSUs which will vest in installments of 109 on 5/7/2026, 110 on 5/7/2027, and 114 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 90 Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:00 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 2,163 | $300.30 Strike: $300.30 | $649,553.23 |
DisclosureSEC source: 0001127602-24-014851 · form4.xml · derivative · entry 2 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,163 Underlying: Common Stock · 2,163 shares Expires 2034-05-07 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:00 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014851 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,932 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 43 RSUs which will vest on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027; and 333 RSUs which will vest in installments of 109 on 5/7/2026, 110 on 5/7/2027, and 114 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 112 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2024 Filed May 8, 2024 00:31 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 27 | $311.29 | $8,404.83 |
DisclosureSEC source: 0001127602-24-014505 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,599 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 43 RSUs which will vest on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 112 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2024 Filed May 7, 2024 00:24 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 27 | $277.37 | $7,488.99 |
DisclosureSEC source: 0001127602-24-014351 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,626 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 43 RSUs which will vest on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 121 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 30, 2024 Filed May 1, 2024 23:50 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 17 | $276.38 | $4,698.46 |
DisclosureSEC source: 0001127602-24-013810 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,653 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 43 RSUs which will vest on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 125 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 23:59 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 146 | $268.87 | $39,255.02 |
DisclosureSEC source: 0001127602-24-010847 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,670 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 129 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:24 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 418 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009238 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,799 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 115 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 05, 2023 Filed Nov 8, 2023 01:12 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 183 | $269.86 | $49,384.38 |
DisclosureSEC source: 0001127602-23-026975 · form4.xml · nonDerivative · entry 2 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 101 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 05, 2023 Filed Nov 8, 2023 01:12 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 66 | $269.86 | $17,810.76 |
DisclosureSEC source: 0001127602-23-026975 · form4.xml · nonDerivative · entry 1 Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,550 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.